Scholar Rock

Yahoo Finance • 20 days ago

Scholar Rock, A Top 10% Stock, Dives After Catalent Issues Hamper SMA Drug

Shares of Scholar Rock tumbled Tuesday after the FDA rejected the company's spinal muscular atrophy drug, citing concerns at a plant. Continue Reading Ver comentarios... Full story

Yahoo Finance • 20 days ago

FDA Issues Complete Response Letter (CRL) for Apitegromab as a Treatment for Patients with Spinal Muscular Atrophy (SMA) Solely Related to Observations Identified at Catalent Indiana LLC Fill-Finish Facility

No other approvability issues cited in CRL Scholar Rock intends to resubmit the apitegromab Biologics License Application (BLA) upon resolution of Catalent Indiana LLC-related observations CAMBRIDGE, Mass., September 23, 2025--(BUSINESS... Full story

Yahoo Finance • 2 months ago

Scholar Rock (SRRK) Jumps 14% on Bargain-Hunting, Price Down 20.4% YTD

We recently published 10 Big Names With Surprising Gains. Scholar Rock Holding Corp. (NASDAQ:SRRK) is one of Wednesday’s best performers. Scholar Rock saw its share prices jump by 14.26 percent on Wednesday to close at $34.4 apiece as inv... Full story

Yahoo Finance • 2 months ago

Scholar Rock stock rating initiated at Buy by Jefferies with $50 target

Investing.com - Jefferies has initiated coverage on Scholar Rock (NASDAQ:SRRK) with a Buy rating and a price target of $50.00, according to a research note released Thursday. The company, currently valued at $3.3 billion, has received stro... Full story

Yahoo Finance • 2 months ago

Scholar Rock jumps following Regeneron Eylea update

[graph from neons 1] Jonathan Kitchen * An update from Regeneron Pharmaceuticals (NASDAQ:REGN [https://seekingalpha.com/symbol/REGN]) earlier Wednesday regarding [https://seekingalpha.com/news/4487554-regenerons-eylea-injection-review-d... Full story

Yahoo Finance • 2 months ago

Earnings call transcript: Scholar Rock's Q2 2025 EPS miss sends stock down 14%

Scholar Rock Holding Corp (SRRK) reported its second-quarter 2025 earnings, revealing an EPS of -0.98, which fell short of the anticipated -0.66, marking a 48.48% negative surprise. This led to a premarket stock price decline of 14.44%, wi... Full story

Yahoo Finance • 2 months ago

Scholar Rock Holding Corp (NASDAQ:SRRK) Reports Q2 2025 Wider Loss but Market Shows Optimism Ahead of Key FDA Decision

SCHOLAR ROCK HOLDING CORP (NASDAQ:SRRK [https://www.chartmill.com/stock/quote/SRRK]) REPORTS Q2 2025 RESULTS: WIDER LOSS THAN EXPECTED, MARKET REACTS POSITIVELY Scholar Rock Holding Corp posted a net loss of $110 million, or $0.98 per sha... Full story

Yahoo Finance • 2 months ago

Scholar Rock Reports Second Quarter 2025 Financial Results and Highlights Business Progress

FDA accepted the apitegromab BLA under priority review with a PDUFA target action of September 22, 2025; finalizing U.S. commercial launch preparations European Medicines Agency validatedMarketing Authorisation Application (MAA), and regu... Full story

Yahoo Finance • 3 months ago

Scholar Rock CSO Mo Qatanani sells $828,898 in shares

Mo Qatanani, Chief Scientific Officer of Scholar Rock Holding Corp (NASDAQ:SRRK), sold 24,066 shares of common stock on July 8, 2025, according to a Form 4 filing with the Securities and Exchange Commission. The company, currently valued... Full story

Yahoo Finance • 3 months ago

Scholar Rock Q1 2025 slides: apitegromab advances toward FDA approval with priority review

Introduction & Market Context Scholar Rock Holding Corp (NASDAQ:SRRK) presented its Q1 2025 Business Update on May 14, highlighting significant progress toward the potential launch of its lead candidate apitegromab for Spinal Muscular At... Full story

Yahoo Finance • 4 months ago

Notable healthcare headlines for the week: Eli Lilly, Novavax and Sarepta Therapeutics in focus

Wall Street’s major market averages seesawed back and forth on Friday and finished mixed as Federal Reserve Governor Christopher Waller hinted at potential rate cuts in July. The S&P 500 Health Care Index Sector (NYSEARCA:XLV [https://see... Full story

Yahoo Finance • 4 months ago

Muscle-preserving drugs could generate over $30 billion in sales by 2035, TD Cowen says

By Bhanvi Satija (Reuters) -Treatments designed to help patients preserve muscle while losing weight with popular obesity drugs by Eli Lilly and Novo Nordisk could generate more than $30 billion in sales by 2035, analysts at TD Cowen said... Full story

Yahoo Finance • 4 months ago

Google, Eli Lilly dip amid Friday's market cap stock movers

Friday’s trading session is showcasing a mix of retreats and advances across the stock market, with mega-cap and large-cap stocks experiencing notable intra-day movements. From tech giants to pharmaceutical leaders, the market is reacting... Full story

Yahoo Finance • 4 months ago

Stocks making the biggest moves midday: Nucor, Sunrun, Affirm, Zoetis, Circle and more

Check out the companies making headlines in midday trading: Steel stocks — Shares of steel producer Nucor jumped more than 3%. The company issued rosy guidance for its second-quarter earnings, calling for $2.55 to $2.65 per share, while Fa... Full story

Yahoo Finance • 4 months ago

Oracle, JPMorgan Lead Market Cap Stock Movers on Wednesday

Wednesday’s trading session is showcasing significant movements across various market cap categories, with stocks like Oracle Corp (NYSE:ORCL) and JP Morgan Chase (NYSE:JPM) leading the gains in the mega-cap space, while Regencell Bios... Full story

Yahoo Finance • 4 months ago

Scholar Rock lead asset causes higher quality weight loss with Lilly’s obesity drug

[Two injectors dosing pens for subcutaneous injection of antidiabetic medication or anti-obesity medication hovering over a blue background. Yellow measuring tape around the injectors.] Alones Creative Scholar Rock (NASDAQ:SRRK [https://s... Full story

Yahoo Finance • 4 months ago

Jefferies sees promising M&A targets in biotech sector amid stabilizing market

Jefferies has identified several biotechnology companies as promising merger and acquisition targets, highlighting firms with de-risked or commercial-stage assets that could generate significant sales. In a recent research note, the firm s... Full story

Yahoo Finance • 2 years ago

Insider Edward Myles Sells 6,634 Shares of Scholar Rock Holding Corp (SRRK)

Edward Myles, COO & CFO of Scholar Rock Holding Corp (NASDAQ:SRRK), sold 6,634 shares of the company on January 16, 2024, according to a recent SEC filing. The transaction was executed at an average price of $15.93 per share, resulting in... Full story

Yahoo Finance • 3 years ago

Scholar Rock Reports Full Year 2022 Financial Results and Highlights Business Progress

- Enrollment of pivotal Phase 3 SAPPHIRE trial evaluating apitegromab on track for completion in 2023, and 36-month extension data from Phase 2 TOPAZ trial expected in mid-2023 - Phase 1 DRAGON trial of SRK-181 continues to advance with b... Full story

Yahoo Finance • 3 years ago

New Phase 2 TOPAZ Trial Data Indicate Positive Trends in Quality-of-Life Measures Over 24 Months with Apitegromab for Nonambulatory Patients with Types 2 and 3 SMA

- Tertiary endpoint data show trends of continuous improvement in activities of daily living, fatigue, and endurance over 24 months - These data indicate the potential for sustained improvement in quality-of-life measures for patients wit... Full story